Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation
Status:
Completed
Trial end date:
2021-09-10
Target enrollment:
Participant gender:
Summary
Primary purpose of the study is to see if rifaximin can improve the balance of bacteria
within the gut, which has been shown to improve transplant outcomes. It will also assess
whether rifaximin can reduce the risk of infection in blood/marrow transplant (BMT).